30.00
Schlusskurs vom Vortag:
$34.59
Offen:
$34.86
24-Stunden-Volumen:
42,373
Relative Volume:
0.85
Marktkapitalisierung:
$200.92M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.12M
KGV:
-13.04
EPS:
-2.3
Netto-Cashflow:
$-6.82M
1W Leistung:
-25.61%
1M Leistung:
-5.36%
6M Leistung:
+550.76%
1J Leistung:
+4,599%
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Firmenname
Monopar Therapeutics Inc
Sektor
Branche
Telefon
(847) 388-0349
Adresse
1000 SKOKIE BLVD SUITE 350, WILMETTE
Vergleichen Sie MNPR mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
MNPR
Monopar Therapeutics Inc
|
30.00 | 200.92M | 0 | -7.12M | -6.82M | -2.30 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
555.11 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
238.51 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-03-19 | Fortgesetzt | Piper Sandler | Overweight |
2025-01-10 | Eingeleitet | Piper Sandler | Overweight |
2024-10-11 | Eingeleitet | Rodman & Renshaw | Buy |
2021-01-28 | Eingeleitet | ROTH Capital | Buy |
Monopar Therapeutics Inc Aktie (MNPR) Neueste Nachrichten
Jones Trading Reiterates “Hold” Rating for Monopar Therapeutics (NASDAQ:MNPR) - Defense World
HC Wainwright Issues Negative Forecast for MNPR Earnings - Defense World
What is HC Wainwright’s Forecast for MNPR FY2029 Earnings? - Defense World
Monopar Therapeutics downgraded to Hold from Buy at JonesResearch - TipRanks
We Think Monopar Therapeutics (NASDAQ:MNPR) Can Easily Afford To Drive Business Growth - Yahoo Finance
Monopar Therapeutics (NASDAQ:MNPR) Receives “Buy” Rating from HC Wainwright - Defense World
Top 5 Small-cap Biotech Stocks of 2025 - Nasdaq
Monopar Therapeutics Stock Hits 52-Week High at $38.91 - MSN
Monopar Therapeutics Inc: Strategic Advancements and Promising Financial Projections Justify Buy Rating - TipRanks
Buy Rating for Monopar Therapeutics Inc: Strategic Advancements and Promising Financial Outlook - TipRanks
Monopar Therapeutics reports Q4 EPS ($2.23) vs. (60c) last year - TipRanks
Monopar Therapeutics sees cash runway through December 31, 2026 - TipRanks
Monopar Therapeutics SEC 10-K Report - TradingView
Monopar Secures 2-Year Runway with $60M War Chest, Advances Wilson Disease Drug - Stock Titan
MNPR Stock Price and Chart — NASDAQ:MNPR - TradingView
Here's Why Momentum in Monopar Therapeutics (MNPR) Should Keep going - Yahoo Finance
Piper Sandler Reaffirms “Overweight” Rating for Monopar Therapeutics (NASDAQ:MNPR) - Defense World
Monopar Therapeutics (MNPR) to Release Quarterly Earnings on Thursday - Defense World
Monopar a new overweight at Piper Sandler on rare disease asset - Seeking Alpha
Piper Sandler sets Monopar stock at $76 with Overweight rating - Investing.com
Buy Rating for Monopar Therapeutics Inc. Driven by Strategic Acquisition and ALXN1840 Potential - TipRanks
Piper Sandler sets Monopar stock at $76 with Overweight rating By Investing.com - Investing.com UK
(MNPR) Trading Report - news.stocktradersdaily.com
Monopar Therapeutics Inc.'s (NASDAQ:MNPR) 19% loss last week hit both individual investors who own 33% as well as institutions - Simply Wall St
Monopar Therapeutics: Strong Data, But There Are Risks (NASDAQ:MNPR) - Seeking Alpha
Monopar Therapeutics appoints new CFO - Investing.com
Monopar Therapeutics Appoints Quan Vu as New CFO - TipRanks
Monopar Therapeutics Inc Says On Feb 28, CFO Karthik Radhakrishnan'S Employment Terminated - Marketscreener.com
Monopar Therapeutics appoints new CFO By Investing.com - Investing.com Australia
Monopar Therapeutics appoints new board member - Investing.com
Monopar Therapeutics appoints new board member By Investing.com - Investing.com UK
Monopar Therapeutics Appoints Lavina Talukdar to Board - TipRanks
Trend Tracker for (MNPR) - Stock Traders Daily
Copper wired: Monopar to electrify Wilson disease? - BioWorld Online
Q1 EPS Estimate for Monopar Therapeutics Raised by Analyst - MarketBeat
Learn to Evaluate (MNPR) using the Charts - Stock Traders Daily
Brookline Capital Management Forecasts MNPR Q1 Earnings - Defense World
Monopar's Incredible Journey From $5 To $50 In Less Than 5 Months - RTTNews
Why Monopar Therapeutics Inc (MNPR) Is Skyrocketing So Far In 2025 - MSN
Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
What's Going On With Cancer-Focused Monopar Therapeutics Stock Today? - MSN
What is HC Wainwright’s Forecast for MNPR FY2026 Earnings? - Defense World
Analysts Set Expectations for MNPR FY2029 Earnings - MarketBeat
What is HC Wainwright's Forecast for MNPR FY2026 Earnings? - MarketBeat
Monopar Therapeutics Stock Hits 52-Week High at $38.91 By Investing.com - Investing.com South Africa
Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics - PR Newswire
Monopar Therapeutics price target raised to $40 from $22 at H.C. Wainwright - Yahoo Finance
Monopar Therapeutics (NASDAQ:MNPR) Price Target Raised to $40.00 - MarketBeat
Finanzdaten der Monopar Therapeutics Inc-Aktie (MNPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Monopar Therapeutics Inc-Aktie (MNPR) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Radhakrishnan Karthik | Chief Financial Officer |
Oct 28 '24 |
Buy |
16.25 |
1,550 |
25,188 |
1,550 |
Cittadine Andrew | Chief Operating Officer |
Jun 20 '24 |
Buy |
0.74 |
20,508 |
15,254 |
186,132 |
Cittadine Andrew | Chief Operating Officer |
Jun 18 '24 |
Buy |
0.86 |
12,000 |
10,320 |
165,624 |
Cittadine Andrew | Chief Operating Officer |
Jun 14 '24 |
Buy |
0.93 |
12,000 |
11,176 |
141,624 |
Cittadine Andrew | Chief Operating Officer |
Jun 13 '24 |
Buy |
0.91 |
12,000 |
10,920 |
129,624 |
Cittadine Andrew | Chief Operating Officer |
Jun 17 '24 |
Buy |
0.90 |
12,000 |
10,799 |
153,624 |
Cittadine Andrew | Chief Operating Officer |
Jun 04 '24 |
Buy |
0.78 |
12,000 |
9,360 |
117,624 |
Cittadine Andrew | Chief Operating Officer |
Jun 03 '24 |
Buy |
0.76 |
12,000 |
9,120 |
105,624 |
Cittadine Andrew | Chief Operating Officer |
May 31 '24 |
Buy |
0.64 |
12,000 |
7,732 |
93,624 |
Cittadine Andrew | Chief Operating Officer |
May 30 '24 |
Buy |
0.64 |
12,000 |
7,676 |
81,624 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):